Immunovant IMVT-1402 RA Win Shapes a $6.3 Billion Bet on the FDA

Immunovant's fiscal second quarter ended September 30, 2026, produced a GAAP loss of $0.47 per share, beating the consensus estimate of negative $0.72. The improvement was largely a spending story: research and development costs fell to $85.0 million from $114.2 million a year earlier, driven by the wind-down of batoclimab trials and favorable timing on contract manufacturing payments. Net loss narrowed to $97.2 million from $126.5 million in the year-ago period.

IMVT-1402 at the 600 mg dose met the primary endpoint in a potentially registrational trial in difficult-to-treat rheumatoid arthritis, with 92.5% of patients maintaining an ACR20 response at Week 28, compared with 75.6% on placebo. That result, with a p-value of 0.0139, clears the bar for statistical significance and opens the door to a conversation with the FDA about a registrational path, which Immunovant expects to hold later this year.

The 300 mg dose did not separate from placebo, posting an ACR20 rate of 75.0% with a p-value of 0.9426, and the secondary endpoints measuring CDAI and SDAI changes at 600 mg did not reach statistical significance. Exploratory ACR50 data at 600 mg showed 80.0% versus 56.1% on placebo, though that figure carries only nominal significance. How the FDA weighs the totality of this evidence is the question that will define how much of the company's $6.3 billion valuation is justified.

Immunovant's cash position of $722.3 million is expected to fund operations through a potential commercial launch of IMVT-1402 in Graves' disease, though that figure has declined from $902.1 million over the past six months. Topline data from potentially registrational trials in Graves' disease and myasthenia gravis are expected in calendar 2027, with CIDP data following in 2028. The Sjögren's disease program, by contrast, is unlikely to advance beyond its ongoing Phase 2 trial, a deprioritization the company attributed to the evolving competitive landscape.

The upcoming FDA meeting on the RA program is the near-term event that matters most. A clear registrational pathway would validate the 600 mg dose as a commercial candidate across multiple indications, while a more cautious agency response raises questions about the breadth of the program and the adequacy of secondary endpoint data. Investors will also be watching for any update on whether the company needs to raise additional capital beyond its current cash runway.